Our Keynote bladder cancer clinical trials are studying pembrolizumab to see if it may help patients with bladder cancer. Pembrolizumab is an investigational immunotherapy that targets the PD-1 pathway.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
Clinical trials for bladder cancer are underway and currently enrolling patients. If you have patients with bladder cancer, you may want to consider a Keynote trial. To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Study of Pembrolizumab in Participants With High Risk Non-muscle Invasive Bladder Cancer||057||Bladder Cancer||Phase 2||Recruiting|
|A Study of Pembrolizumab Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer||045||Urothelial Cancer||Phase 3||Active, not recruiting|
|Study of Pembrolizumab in Participants With Advanced Urothelial Cancer||052||Urothelial Cancer||Phase 2||Active, not recruiting|
|Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma||361||Urothelial Carcinoma Associated 1 RNA, Human||Phase 3||Active, not recruiting|
|Efficacy and Safety of Pembrolizumab in Combination With Bacillus Calmette-Guerin in High-Risk Non-Muscle Invasive Bladder Cancer||676||High-risk Non-muscle Invasive Bladder Cancer||Phase 3||Not yet recruiting|